Research Article
Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients
Table 2
Demographic and clinical characteristics of the patients.
| | Characteristics | aaPRP treatment |
| | Characteristics | | Age, yr | 52.1 ± 8.89 | | Male sex, % | 40 | | Female sex, % | 60 | | No. of coexisting conditions, no./total no. (%) | | | Two | 4/10 (40) | | Three | 4/10 (40) | | Four | 2/10 (20) | | Coexisting conditions, no./total no. (%) | | | Type 2 diabetes | 4/27 (14.81) | | Hypertension | 2/27 (7.41) | | Congestive heart failure (CHF) | 3/27 (11.11) | | Disseminated intravascular coagulation (DIC) | 7/27 (25.93) | | Community-acquired pneumonia (CAP) | 4/27 (14.81) | | Coronary artery disease (CAD) | 1/27 (3.70) | | Chronic kidney disease (CKD) | 1/27 (3.70) | | Lung pulmonary tuberculosis | 1/27 (3.70) | | Atrial fibrillation | 1/27 (3.70) | | Hypo-Na | 1/27 (3.70) | | Metabolic encephalopathy | 1/27 (3.70) | | Happy hypoxia | 1/27 (3.70) |
|
|
